
The HEALEY ALS Platform Trial announces first participants enrolled for investigational product SLS-005 (Trehalose)
First participants for the investigational product SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion).
Learn MoreSafe Care CommitmentGet the latest news on COVID-19, the vaccine and care at Mass General.Learn more
Sean M. Healey & AMG Center for ALS
First participants for the investigational product SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion).
Learn MoreThe Athletic features a moving profile of NFL star, writer and ALS activist Tim Green and his family.
The Morris ALS Principles award honored the HEALEY ALS Platform Trial team for their work to include people with ALS in planning and development of the trial and for using Expanded Access Protocols to give more people access to potential therapies.
Join our quest to discover life-saving therapies for individuals who are affected by ALS. The key to our success is our dedication to collaboration. At the Sean M. Healey and AMG Center for ALS at Mass General, we partner with the best clinician-scientists, our patients and friends like you to turn laboratory successes into promising therapies.